OR WAIT null SECS
May 19, 2021
Sandoz plans to strengthen its European antibiotics manufacturing network by expanding its production capabilities in Kundl, Austria, and Palafolls, Spain.
Colorcon’s new suite will provide clients with capabilities to develop prototype tablets or capsule dosage forms when API quantity is limited or the API potency requires a higher level of protection.
May 15, 2021
The latest news about biologics facilities includes various expansions, new locations, and acquisitions in the bio/pharmaceutical space.
May 03, 2021
This new collaboration between Vyant Bio, Ordaōs Bio, and Cellaria mitigates risk in the drug discovery process using artificial intelligence and in-vitro “avatar” clinical trials.
Both the European Commission and FDA have granted approval to GlaxoSmithKline’s Jemperli (dostarlimab) for treating endometrial cancer.
Applying a QbD approach helps address excipient variability and other quality features.
April 26, 2021
Lonza’s new complex will occupy 2000 m2 of the facility with six levels of manufacturing space and will provide room for future small-molecule technologies expansion.
April 22, 2021
DFE’s new line will offer market purity and low endotoxin excipients for use in formulation, while providing drug developers and manufacturers high-quality excipient technology and services.
April 03, 2021
Intensified and distributed manufacturing approaches create flexible, local capacity.
Topical drugs are attractive to patients, but these complex products pose challenges for formulators.
